IntoCell, which was newly listed on the KOSDAQ market on 23rd, is showing strength in early trading.

IntoCell CI.

As of 9:03 a.m. on this day, IntoCell is trading at 34,800 won, up 17,800 won (104.71%) from its offering price.

IntoCell is a corporation founded by CEO Park Tae-kyo, who jointly developed the antibody-drug conjugate (ADC) platform with LigaChem Biosciences. The technology that IntoCell possesses is the platform 'Opas,' which specializes in the 'linker' that connects antibodies and drugs. It circulates stably in the body while maintaining its structure but separates and releases the drug after reaching the desired location.

IntoCell plans to sign a technology export contract within this year. The company notes that it is proceeding with contracts centered around royalties, confident about commercialization.

IntoCell recorded a competition ratio of 1,151.5 to 1 in institutional demand forecasting and a competition ratio of 2,268.9 to 1 during the general investor subscription conducted from 13th to 14th.